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Abstract Several autoin£ammatory diseases with distinct clin-
ical manifestations have been associated with sequence varia-
tions in the gene products PYPAF1/CIAS1 and NOD2/
CARD15. Both proteins belong to the PYD/CARD-containing
family of apoptosis regulators and activators of pro-in£amma-
tory caspases. To gain insight into the dysfunctional role of
sequence alterations, we assembled a structure-based multiple
sequence alignment of family members and related proteins.
This allowed us to analyze the putative e¡ect of the alterations
on the function of nucleotide-binding (NACHT) and leucine-rich
repeat (LRR) domains shared by the family members. In sup-
port of this analysis, we carefully selected template structures
for the NACHT and LRR domains and mapped the genetic
variations onto 3D domain models. Additionally, we propose a
model of the NACHT and LRR domain complex. Our study
revealed that many of the disease-associated sequence variants
are located close to highly conserved sequence regions of func-
tional relevance and are spatially adjacent in the predicted 3D
structure. The implications on the domain functions such as
NTP-hydrolysis or oligomerization are discussed.
5 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Several sequence variations in the gene products PYPAF1
(PYRIN-containing APAF-1-like protein) and NOD2 (nucle-
otide-binding oligomerization domain protein 2) have been
associated with clinically distinct diseases, which are charac-
terized pathophysiologically by similar autoin£ammatory pro-
cesses. The PYPAF1 and NOD2 proteins are members of a
cytoplasmic protein family named CATERPILLER, which is
involved in apoptosis regulation and in£ammatory immune
responses. Recently, several comprehensive reviews [1^11]
and two online databases [12,13] have been published on
this family and the related disorders.
Genetic variants of PYPAF1 are linked to chronic infantile
neurological cutaneous and articular syndrome (CINCA, also
known as neonatal-onset multisystem in£ammatory disease
NOMID), familial cold autoin£ammatory syndrome (FCAS,
also called familial cold urticaria FCU), and Muckle^Wells
syndrome (MWS) [14^20]. Single nucleotide polymorphisms
(SNPs) in the NOD2 gene predispose to Blau syndrome
(BS) [21,22] and Crohn’s disease (CD) [23^26], which is one
of the two main types of chronic in£ammatory bowel disease
[27,28].
The CATERPILLER family consists of about twenty hu-
man proteins, which share a homologous domain architecture
that consists of N-terminal e¡ector-binding PYD or CARD
domains, one centrally located oligomerization NACHT
NTPase domain (including a yet uncharacterized C-terminal
NACHT-associated domain extension NAD), and one ligand-
recognition C-terminal leucine-rich repeat (LRR) domain
(Fig. 1). This protein family belongs to a larger superfamily
of regulators of apoptotic and stress signaling pathways,
which includes another family containing the human apopto-
tic protease-activating factor APAF-1 and its Caenorhabditis
elegans ortholog CED-4 [29]. This other family shows a sim-
ilar domain architecture with a CARD domain followed by a
NB-ARC NTPase domain (also termed AP-ATPase domain)
[30,31] instead of the closely related NACHT domain [32].
Recently, the mammalian orthologs of human PYPAF1,
PYPAF5, NOD1, and NOD2 were identi¢ed [33].
The PYD/PYRIN domain is named after the protein
pyrin, the product of the familial Mediterranean fever gene
[34,35], and is also called DAPIN or PAAD domain [36^40].
It is homologous to the CARD (caspase-activating recruit-
ment) [41], DD (death), and DED (death-e¡ector) domains,
whose 3D structures reveal a highly conserved compact bun-
dle of six-anti-parallel K-helices as common domain fold
[42,43]. Each of the four described domain families binds
to other family members through homotypic interactions in
order to downstream transduce a regulatory signal on apopto-
sis.
The PYD domain of PYPAF1 interacts selectively with the
PYD domain of the PYD-CARD adaptor protein ASC,
which activates caspase-1 [44,45]. In contrast, the CARD do-
main of NOD2 assembles with the CARD domain of the
serine-threonine kinase RICK (also called RIP2/CARDIAK)
[5]. Generally, both the PYD and CARD domain families
participate in the regulation of pro-in£ammatory signaling
pathways by the activation of NF-UB and pro-caspase-1; cas-
pase-1 then processes pro-interleukin-1L/-18 into active cyto-
kines. It is hypothesized that a defect in the signaling cascade
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results in an impaired innate immunity, which leads to in£am-
matory processes.
NACHT is an acronym for the founding family members
NAIP (neuronal apoptosis inhibitor protein), CIITA (major
histocompatibility complex (MHC) class II transactivator),
HET-E (plant het gene product involved in vegetative incom-
patibility), and TP1 (telomerase-associated protein 1). Most of
the proteins with an NB-ARC or NACHT domain mediate
self-oligomerization and are predicted or shown to have ATP-
ase activity [4], but CIITA and HET-E are GTPases [46,47].
The transactivator CIITA has an transcriptional activation
domain (AD) preceding the NACHT domain and regulates
the expression of MHC class II genes [48,49]. Dendritic cell-
speci¢c splice variants of CIITA contain an additional N-ter-
minal CARD before the AD [50]. Several mutations in CIITA
cause type II bare lymphocyte syndrome (BLS), a severe im-
munode¢ciency disorder [51^57].
In contrast to the unknown function of the LRR domain in
PYPAF1, the homologous LRR domains of NOD1 and
NOD2 have been shown to function as speci¢c sensors of
bacterial peptidoglycan through muramyl dipeptide detection
[7,58,59]. Generally, it is assumed that the LRR domain of the
described proteins recognizes speci¢c pathogen-derived mole-
cules. This is in analogy to mammalian Toll-like receptors
(TLRs) and plant disease resistance gene products (R pro-
teins), which are all part of the surprisingly similar innate
immune system of plants, animals, and man [1^11,60]. R pro-
teins also possess a NB-ARC domain besides their extracellu-
lar C-terminal LRR domain, which they have in common
with TLRs [61^63]. However, R proteins carry a non-homol-
ogous TIR (Toll and interleukin-1 receptor) or CC (coiled-
coil) domain [64^70] for intracellular downstream signaling
instead of a CARD or PYD domain.
The analysis of the structural localization of the sequence
variants can give important insight into the potential disease
mechanism on a molecular level. Because most disease-asso-
ciated genetic variations are found in the NACHT domain, we
assembled a manually curated multiple sequence alignment of
members of the NACHT protein domain family. The align-
ment also includes carefully selected NTPases whose struc-
tures have been determined crystallographically and re£ect
speci¢c characteristics of the NACHT domain and its second-
ary structure prediction. This enabled us to map the sequence
variations found in the NACHT domain onto its predicted 3D
structure in order to understand functional implications. In
addition, we provide a hypothetical model of the NACHT
and LRR domain complex and show that other sequence
variants may a¡ect the domain^domain interface. Finally,
we draw conclusions on the potential dysfunctional role of
the disease-associated sequence variants and suggest suppor-
tive experiments.
2. Materials and methods
All protein sequences were retrieved from the SWISS-PROT/
TrEMBL (SPTrEMBL) database [71]. Their accession numbers are
given in the caption of Fig. 1. The hierarchical classi¢cation and
structural neighbors of protein structures downloaded from the
PDB [72] were obtained from the SCOP database (release 1.63 of
May 2003) [73]. The secondary structure assignments to PDB struc-
tures were taken from the DSSP database [74]. A single capital letter
appended to the actual PDB identi¢er denotes the chosen structure
chain. We employed the BLAST program [75] to search the PDB.
We used the web server PSIPRED to predict the secondary struc-
ture [76]. This server showed top performance close to a three-state
accuracy of 80% according to a recent evaluation [77]. Multiple se-
quence alignments were constructed by means of CLUSTAL W [78]
and improved manually based on the predicted secondary structure
and pairwise structure superpositions as returned by the program CE
(combinatorial extension) [79]. The root mean square deviations
(RMSDs) with the associated sequence identities were taken from
the CE superpositions. In order to obtain alternative superpositions,
we employed the superposition web server ProSup [80].
We explored all standard fold recognition tools available via the
online meta-server BioInfo.PL [81], which contacts a dozen other
state-of-the-art prediction servers (whose names are listed on the
web site http://BioInfo.PL/Meta/). Its 3D-Jury system allows for com-
paring and evaluating the predicted 3D models conveniently in a
consensus view [82]. We also compared the 3D predictions with the
results from our fold recognition server Arby [83,84]. To model the
protein structure of the NACHT domain, we submitted the sequence-
structure alignment to the WHAT IF modeling server [85] and applied
the side chain placement program SCWRL [86] to the resulting 3D
model (the side chain conformation of amino acids that are identical
in both aligned sequences was preserved). Alternatively, we used the
completely automatic 3D-JIGSAW modeling server [87] to obtain
full-atom 3D models of the LRR domain. The sequence alignments
shown in the ¢gures were prepared in the SEAVIEW editor [88] and
illustrated using the web tool ESPript [89]. The protein structure im-
ages were drawn in the Accelrys Discovery Studio ViewerLight. The
online version of this article contains supplementary material, and our
web site will provide additional pictures.
3. Results and discussion
3.1. Multiple sequence alignment of NACHT domains
We compiled a list of human PYD/CARD-containing
NACHT-LRR proteins as follows: PYPAF1-8, DEFCAP,
CLAN, NOD1/2, CIITA (synonymous protein names are
listed in the caption of Fig. 1). We then assembled a multiple
sequence alignment of their NACHT domains (Fig. 2 and
Fig. 1. Domain architectures of the human proteins PYPAF1-8,
DEFCAP, CLAN, NOD1, NOD2, CIITA, APAF-1, and C. elegans
CED-4. Note that the NACHT domain is an NTPase domain with
C-terminal helical extension subdomains of an additional NACHT-
associated domain NAD, and DEFCAP has additional C-terminal
domains, including an intermediate FFIND (‘function to ¢nd’)
domain. Also, the proteins actually have a slightly di¡ering number
of LRR units. In contrast to APAF-1, CED-4 lacks the WDR
(WD-40 repeat) domain, which substitutes the LRR domain in
APAF-1. The SPTrEMBL accession numbers and synonymous
names of the selected proteins are as follows: PYPAF1/CIAS1/
CRYOPYRIN/NALP3, Q96P20; PYPAF2/NALP2/NBS1/PAN1,
Q9NX02; PYPAF3/NALP7/NOD12, Q8WX94; PYPAF4/NALP4/
PAN2, Q96MN2; PYPAF5/NALP6/PAN3, P59044; PYPAF6/
NALP11/NOD17, P59045; PYPAF7/MONARCH-1/NALP12/PAN6,
P59046; PYPAF8/MATER/NALP5, P59047; DEFCAP/CARD7/
NALP1/NAC, Q9C000; CLAN/CARD12/IPAF, Q9NPP4; NOD1/
CARD4, Q9Y23; NOD2/CARD15/IBD1, Q9HC29; CIITA/
MHC2TA, P33076; APAF-1, O14727; CED-4, P30429.
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Web Fig. A) and improved it manually based both on the
secondary structure prediction for PYPAF1, NOD2, and
CIITA and pairwise superpositions of related PDB structures,
whose selection is described below. We also included APAF-1
and CED-4 with their NACHT-related NB-ARC domain and
the corresponding secondary structure predictions into the
alignment. The multiple alignment indicates that the NAD
extension of the NACHT domain consists of three helical
subdomains NAD1, NAD2, and NAD3, which are connected
by linker regions of highly variable lengths. Sequence identi-
Fig. 2. Structure-based multiple sequence alignment of NACHT and NB-ARC domains including the PDB structures 1fnnA, 1bmfF, 1e32A,
and 1ksfX (a multiple alignment covering the NAD extension is shown in Web Fig. A). The DSSP secondary structures and the corresponding
predictions by the PSIPRED server are depicted in the upper and lower part of each alignment row (K-helices are represented by curled lines,
L-strands by horizontal arrows). The alignment columns with strictly conserved residues are highlighted in dark gray boxes, those in which
more than 60% of the residues are physico-chemically equivalent are shown in light gray boxes. Solid text labels denote disease-associated var-
iants and other sequence variations. Dotted labels indicate alanine substitutions of a mutagenesis study with the close homolog CDC18 of
CDC6 (1fnnA). Important residues involved in nucleotide-binding are also annotated.
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ties derived from the multiple alignment of the NTPase do-
mains (Fig. 2) can be found in the Web Table.
3.2. Selection of modeling template
Based on the results that were returned by our in-house fold
recognition server Arby and by the BioInfo.PL meta-server
and its 3D-Jury system, we selected the PDB structures
1fnnA, 1e32A, and 1ksfX/1jbkA as modeling templates for
the extended NACHT domain of PYPAF1 and NOD2. The
ATPase domains of 1fnnA, 1e32A, and 1ksfX/1jbkA are the
N-terminal domains of two consecutive ATPase domains of
the cell division control protein Cdc6 from Pyrobaculum aero-
philum [90], of the murine membrane fusion ATPase p97 (also
known as vasolin-containing protein VCP) [91], and of the
highly homologous Escherichia coli chaperone heat shock
HSP100 family proteases ClpA/ClpB [92,93], respectively.
The ATPase domains of 1fnnA, 1e32A, and 1ksfX/1jbkA
are contained in the same SCOP family, namely that of ex-
tended AAA-ATPases, which possess helical extension subdo-
mains. The ATPase domains of 1fnnA, 1e32A, and 1ksfX/
1jbkA superimpose very well (Web Fig. B) despite low se-
quence identities. In detail, using the ATPase domain of
1fnnA from R18 to P192, 1fnnA and 1e32A superimpose
with an RMSD of 2.8 AT (seq. id. 19%), and 1fnnA and
1ksfX/1jbkA with an RMSD of 3.3 AT /3.1 AT (seq. id. 13%/
12%). For the description of an additional manual veri¢cation
of the automated template selection, see the supplementary
online material. This includes a discussion of the bovine mi-
tochondrial F1-ATPase (PDB identi¢er 1bmfF) [94] and other
more distantly related structural neighbors of the modeling
templates.
3.3. Characteristics of NTPases and the NACHT domain
All the selected structural templates are members of the
large AAA+ family of ATPases, whose sequence motifs of
structural and functional relevance have been discussed exten-
sively in the literature [95^108]. The ATPase domain of 1fnnA
possesses two consecutive C-terminal helical extensions as
subdomains similar to the putative NAD1 and NAD2 subdo-
mains of the CATERPILLER family. However, it remains
unclear whether they are homologous, and we refrained
from aligning them based on secondary structure information
only because of insu⁄cient sequence identity.
The numerous NTPases share a structural core of a central
pleated L-sheet formed by at least four parallel L-strands
£anked by K-helices. The overall shape of the nucleotide-bind-
ing site near the C-termini of the L-strands is strongly pre-
served in all NTPase families despite minor topological di¡er-
ences regarding the number and sequential order of L-strands
and K-helices.
Most NTPases contain two well-characterized consecutive
nucleotide-binding signatures, the Walker A- and B-motifs
[109] (see Fig. 2). The P-loop in the Walker A-motif (consen-
sus sequence A/GxxxxGKT/S, x for any amino acid) wraps
around the polyphosphate moiety of the nucleotide bound by
a strictly conserved lysine. The P-loop is usually preceded by a
L-strand and followed by an K-helix. The Walker B-motif
consists of one to three conserved aspartates/glutamates at
the C-terminus of a L-strand. The ¢rst strand is commonly
involved in anchoring a magnesium ion, which chelates the
bound nucleotide, by hydrogen bonds to Mg2þ-coordinating
water molecules. The second (or third) aspartate/glutamate
usually provides the catalytic carboxylate for NTP-hydrolysis.
Another interesting motif is the sensor-1 region, which con-
tains a conserved polar residue H/N/T/S that contacts the
Q-phosphate of the bound NTP and is thought to discriminate
between ATP and ADP. Particularly, the N-terminal ATPase
domains of 1fnnA, 1e32A, and 1ksfX/1jbkA are involved in
oligomerization of the monomers upon ATP-binding and sub-
sequent ATP-hydrolysis, both of which induce intricate con-
formational changes in the 3D structures [90^93].
3.4. Comparison of structural features
We compared the highly similar secondary structure predic-
tions of PYPAF1, NOD2, and CIITA to the known second-
ary structures of NTPases (Fig. 2). As expected, the secondary
structures of 1fnnA, 1e32A, and 1ksfX/1jbkA match the pre-
diction of the NACHT and NAD domains very well (while
the additional K-helix and L-strand of 1bmfF seems not be
contained in the NACHT domain). Furthermore, the helix
preceding the Walker B-motif in 1fnnA is missing in 1e32A
and 1ksfX/jbkA, but is predicted for the NACHT and NB-
ARC domain. This helix, which follows a strictly conserved
proline, corresponds to the C-terminal half of the aligned
longer helix of 1bmfF (Fig. 2 and Web Fig. E).
Altogether, the structure 1fnnA appears to be the best tem-
plate to model the overall 3D structure of the NACHT do-
main. Unfortunately, the relatively long loop that is predicted
downstream from the Walker B-motif of the NACHT domain
and that contains several disease-associated variants is much
shorter in 1fnnA and only slightly longer in 1e32A and 1ksfX/
1jbkA (Fig. 2). The L-strand and the K-helix at the ends of
this loop in 1e32A, 1ksfX/1jbkA, and 1bmfF match the
corresponding secondary structure elements in 1fnnA (Web
Fig. D). Therefore, this loop may be modeled by a longer
loop from another template such as 1bmfF, resulting in a
hybrid, but less reliable model.
G-proteins have been previously proposed as modeling tem-
plates for the NB-ARC domain of APAF-1 and CED-4
[110,111]. However, the secondary structure elements and
the topology of G-proteins do not match the identi¢ed struc-
tural features of the NACHT domain as accurately as our
AAA-ATPase templates do. The supplementary online mate-
rial contains an additional discussion of structural di¡erences
between the NACHT and the closely related NB-ARC do-
main, including a comprehensive comparison of our selected
template structures to G-proteins.
3.5. Annotation of the multiple sequence alignment
We annotated the structure-based multiple sequence align-
ment in Fig. 2 and Web Fig. A with sequence variations and
critical residues in PYPAF1 and NOD2 and the selected tem-
plate structures. In addition to the known genetic variations
associated with BS and CD, we included other rare variants
into the multiple sequence alignment that are observed in
NOD2 with CD patients and showed two prototypes of pro-
tein dysfunction in experiments [58] : either a two-fold reduc-
tion in both basal NF-UB activity and peptidoglycan-induced
response (PT-II) or an unchanged basal activity, but a major
impairment of the peptidoglycan-response (PT-III). We also
annotated the alignment in Fig. 2 with mutagenesis data that
are available for the close yeast homolog Cdc18 of our tem-
plate CDC6 (1fnnA). Alanine-substitution mutations of
Cdc18 result in three types of phenotypic defect in the cell
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cycle as detailed in [90] : null phenotype characterized by a
complete loss of function (P-N), partial function where cells
arrested with a 2C DNA content (P-A), and slow progression
through S phase due to a failure in the checkpoint response
(P-S).
We used the multiple alignment to map the locations of the
disease-associated sequence alterations contained in the
NACHT and NAD domains of PYPAF1 and NOD2 onto
1fnnA and 1bmfF. In particular, we modeled the 3D structure
NACHT domain for PYPAF1, NOD2, and CIITA using
1fnnA as template. To this end, we extracted pairwise se-
quence-structure alignments from our multiple alignment
Fig. 3. Structural model of the NACHT domain of PYPAF1 (based on the PDB template 1fnnA). While K-helices are colored in red and
L-strands in blue, the locations of disease-associated variants are annotated in yellow. The phosphate-binding lysine K230 and the Mg2þ-an-
choring aspartate D300 are shown as balls-and-sticks together with the bound nucleotide. Note that a long loop in the NACHT domain after
Q306K could not be modeled using 1fnnA. A: Large cluster of variants near the C-termini of the L-strands shown at the bottom of the pic-
ture. B: Rotated view of the model.
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and constructed structural models based on this template.
Alignment insertions and deletions in the modeled 3D struc-
ture are located predominantly in predicted loop regions and
most likely do not a¡ect the structural core. Fig. 3 shows the
resulting model for PYPAF1, annotated with disease-associ-
ated variant residues. Web Fig. F provides another view by
mapping the variants onto the 3D structures of 1fnnA and
1bmfF.
3.6. Localization of sequence variants in the NACHT domain
The two most interesting sequence variations associated
with distinct diseases are R260W (FCAS/MWS) in PYPAF1
and R334W/Q (BS) in NOD2, which are aligned at corre-
sponding positions (Fig. 2 and Web Fig. A). Together with
the disease variant L264H of PYPAF1 (CINCA), they are
located inside a loop near the NTPase active site after the
C-terminus of the preceding L-strand. The three residues
E180, R181, and E184 contained in this region of the F1-
ATPase structure 1bmfF are assumed to be involved in bind-
ing the nucleotide [94,112]. The proline substitution of the
variant L469P (BLS) of CIITA may disrupt the predicted
K-helix.
Another cluster of disease-associated SNPs found in
PYPAF1 consists of D303N (CINCA/MWS), L305P (MWS),
Q306K (CINCA), and F309S (CINCA). They are located
close to the Walker B-motif (Figs. 2 and 3) of the nucleo-
tide-binding site at the C-terminus of the preceding L-strand.
The motif includes the Mg2þ-anchoring aspartate D132 of
1fnnA (in 1bmfF, the aspartate corresponds to D248 and an
additional arginine R252 [94,112]). Interestingly, the variant
D303N is associated with the two clinically di¡erent autoin-
£ammatory diseases CINCA and MWS. Accordingly, it has
been found with a patient who shows an overlap syndrome
with clinical manifestations belonging to both diseases [113].
The variant T348M is also associated with both CINCA
and MWS [20] and locates next to a highly conserved threo-
nine at the C-terminus of another L-strand in the NACHT
domain. We propose that this threonine is equivalent to the
sensor-1 residues H167 in 1fnnA and N349 in 1e32A [101],
which are both aligned to T348. In contrast, we could not
identify a conserved arginine as a so-called sensor-2 residue
in the ¢rst subdomain NAD1. This sensor-2 is found in the
¢rst helical extension subdomain of several ATPases (such as
R241 of 1fnnA) and plays an essential role in oligomerization
and ATPase function [105].
We could not ¢nd a conserved arginine ¢nger either. Such a
¢nger is typical of wheel-like hexameric or heptameric ring-
forming helicases and resides as R359 in 1e32A at the N-ter-
minus of a helix [101]. This ¢nger plays a critical role in
cooperative NTP-hydrolysis and may transduce the chemical
energy of NTP-hydrolysis into conformational changes of the
neighboring protomer upon self-oligomerization [101]. How-
ever, there are arginines at slightly di¡erent positions adjacent
to the mapped arginine of 1e32A in the NACHT domain.
The four missense variants T348M (CINCA/MWS), A352V
(MWS), L353P (FCAS) and H358R (CINCA) in PYPAF1 lie
near the sensor-1 and arginine-¢nger regions around a helix
that connects two L-strands. The variant A374N (CINCA) is
located close to the nucleotide-binding site at the C-terminus
of a predicted, conserved loop after the last L-strand of the
central L-sheet, where Y337 of 1bmfF is known to be impli-
cated in nucleotide-binding.
An analysis of further variants such as V198M (FCAS/
MWS) of PYPAF1 and other sequence alterations contained
in the NAD extension subdomains is provided as supplemen-
tary online material. However, their structural location and
functional role is di⁄cult to judge due to the lack of a reliable
template structure.
3.7. Model of the NACHT and LRR domain complex
While all diseases except of CD and BLS seem to be asso-
ciated solely with sequence variants in the NACHT and NAD
domains, CD is associated with SNPs in the LRR domain.
Also, BLS is often caused by deletions of partial LRR units,
which are tandem repeats of one L-strand followed by one
K-helix and exhibit the consensus motif LxxLxLxxN/CxL
(x can be any amino acid, L can be substituted by V/I/F)
[114]. We modeled the LRR domain for NOD2 by means of
the automatic modeling server 3D-JIGSAW. The sequence-
structure alignment of NOD2 with the template 1a4yA, the
ribonuclease A inhibitor (RNI) [115], which also binds to an-
giogenin [116], is shown in Web Fig. G. This template receives
the most highly signi¢cant E-value of 10310 (seq. id. 30%)
during a PDB search by BLAST with the NOD2 sequence.
It is tempting to speculate that the crystallographically de-
termined complex of an LRR domain and an NTPase domain
provides a reasonable model of the NACHT and LRR do-
main complex either within the same protein or between pro-
tomers after dimerization [117]. It is known that the NACHT
and LRR domains of CIITA mediate self-association and
bind to each other [118]. Indeed, the PDB contains such a
complex, the GTPase Ran and the Ran GTPase activating
protein RanGAP (PDB identi¢er 1k5d, chains A and C, re-
spectively) [119]. RanGAP is contained in the same SCOP
superfamily [114] as the template RNI, but the sequence sim-
ilarity to the LRR domain of NOD2 is lower (seq. id. 25%).
However, the two corresponding chains 1kj5dC and 1a4yA
superimpose very well with an RMSD of 2.6 AT (seq. id. 17%).
Therefore, we superimposed the models of the NACHT and
LRR domains of NOD2 with the structures of human Ran
and RanGAP, respectively, in order to construct a model of
the NACHT and LRR domain complex (Fig. 4 and Web
Figs. H/I and J). However, the model complex needs to be
regarded with some caution because the NACHT domain
model using the template 1fnnA does not superimpose very
well with RAN 1k5dA (RMSD 5.2 AT ). In addition, there are
alternative sequence-structure alignments of the LRR domain
of NOD2 to the RNI structure because of the internal LRRs.
To account for this problem, we employed the ProSup server
instead of the CE program because it provides alternative
superposition alignments. This enabled us to select the best
superposition of the LRR domain model with RanGAP. The
corresponding structure alignment has the highest number of
61 identical residues with an RMSD of 2.4 AT .
Interestingly, the GTPase Ran superimposes well with the
GTPase Ras (RMSD 1.8 AT , seq. id. 26%), which has been
chosen previously as modeling template for APAF-1/CED-4
(for details see the supplementary online material). Both
GTPases belong to the G-protein family within the SCOP
superfamily that contains our NACHT domain template
1fnnA.
3.8. E¡ects of sequence variants in the LRR domain
The predicted models of the NACHT and LRR domains
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and of their complex help to understand the adverse e¡ects of
di¡erent sequence variants. For instance, the variant G908R
(SNP12) associated with CD is located near the predicted
interaction interface of the two domains (Fig. 4). This SNP is
close to the residues D225 and N226 of RanGAP (Web Figs. I
and J), which interact with K130 of Ran [119]. Therefore,
SNP12 can a¡ect the downstream signaling from the peptido-
glycan-sensing LRR units to the CARD domain through the
NACHT domain. This hypothesis agrees well with the exper-
imental measurement of both a reduced basal NF-UB activity
and a decreased peptidoglycan-induced response due to a con-
stitutive defect in NOD2 function caused by SNP12 [58]. It is
not yet possible to interpret the constitutive defect [58] of the
remaining variant R702W (SNP8) in CD because this would
require a more complete domain interaction model including
the NAD extension of the NACHT domain.
The CD-associated variant L1007P (SNP13) leads to a fra-
meshift and the insertion of a premature stop codon. This
mutation results in a drastic structural change with a trun-
cated LRR domain of NOD2 and the deletion of one C-ter-
minal LRR unit outside of the NACHT and LRR domain
interaction interface (Fig. 4 and Web Figs. H/I and J). This
deletion can be expected to directly a¡ect the peptidoglycan-
sensor function of the LRR domain as it is observed exper-
imentally without an impairment of the basal NF-UB activity
[58].
The model of the NACHT and LRR domain complex can
also be used to interpret the results of an experimental ala-
nine-scanning mutagenesis study on the LRR domain of
CIITA. These experiments indicate that mutations within
and around the loops between the L-strand and the following
K-helix of an LRR unit have a detrimental e¡ect on CIITA
function [118,120,121]. These loops are oriented towards the
NACHT domain in the complex model, and some of them
could be involved in domain interactions. Other disease-asso-
ciated variants such as E627G (FCAS) and M662T (CINCA)
of PYPAF1 may also a¡ect those loops based on the pre-
dicted secondary structure (Web Fig. A).
3.9. E¡ects of sequence variants in the NACHT domain
In the NACHT domain, most variants associated with clin-
ically distinct diseases form clusters in adjacent loops close to
the nucleotide-binding C-termini of the L-strands that form
the central L-sheet of NTPases (Fig. 3). It is striking that they
are located on the same side of the protein surface and that
some of them are contained in the active site such as V198M
(FCAS/MWS) and T348M (CINCA/MWS) of PYPAF1. The
di¡erent variants can either disturb NTP-binding and -hydro-
lysis by unfavorable structural changes near the active site or
interfere with domain^domain interactions within the same
protein or between two proteins of a dimer. Indeed, the
NOD2 sequence alteration R334W/Q (BS), which corresponds
to R260W (FCAS/MWS) in PYPAF1, is known to cause a
constitutive dysfunction of NOD2 as revealed by a measured
four-fold increase of the basal NF-UB activity [58]. This se-
quence alteration is located both close to the NTPase active
site and near the predicted interaction interface of the
NACHT and LRR domains (Figs. 3 and 4 and Web Figs.
H/I and J).
Other sequence variations such as H358R (CINCA) of
PYPAF1 are farther away from the nucleotide-binding site
(Fig. 3). However, it is known from mutagenesis experiments
Fig. 4. Model of the complex of the NACHT (top left) and LRR (bottom right) domains of NOD2 (similar illustrations are shown in Web
Figs. H/I and J). The modeled locations of the four sequence variants R334W/Q (BS), R702W (CD, SNP8), G908R (CD, SNP12), and L1007P
(CD, SNP13) are annotated in light gray. The latter SNP13 leads to a frameshift and truncates the C-terminus of NOD2.
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with the L-subunit of the F1-ATPase (1bmfF) that even mu-
tations of amino acids near residues contained in the active
site can indirectly a¡ect the conformation of those residues
and thus impair the ATP-hydrolysis considerably [122,123]
(M209I of E. coli F1-ATPase and H211N of Saccharomyces
cerevisiae F1-ATPase correspond to M214I and H169N in
1bmfF, respectively, see Fig. 2). It is apparent that none of
the disease-associated variants is mapped to essential residues
such as the phosphate-binding lysine in the Walker A-motif or
the Mg2þ-anchoring aspartate in the Walker B-motif. This
fact indicates that NTP-function can be a¡ected by some of
the variants, but is never disabled completely.
4. Conclusions
Using structure-based sequence alignments and models of
the NACHT and LRR domains and their possible complex
formation, we found disease-associated sequence variants
close to highly conserved alignment regions and spatially ad-
jacent in the predicted 3D structure, pointing to very similar
dysfunctional roles. In particular, several variants are ob-
served in the loops that follow the C-termini of the central
L-strands. Some of the variants in the vicinity of the NTPase
active site can interfere with nucleotide-binding, -hydrolysis,
and -release, albeit none has been mapped to residues that are
very critical for NTP-function. Other sequence alterations
may disturb an intricate signal transduction mechanism
from the LRR to the PYD/CARD domain through the
NACHT domain, including essential domain^domain interac-
tions, self-oligomerization upon NTP-binding and important
conformational changes induced by NTP-hydrolysis.
Our ¢ndings are consistent with published experimental ob-
servations on dysfunctional e¡ects of sequence alterations
such as a signi¢cant change of the basal NF-UB activity or
a reduced response to bacterial peptidoglycan. In this context,
it would be very interesting to see related experiments such as
the measurement of the NTPase activity for each sequence
variant. It may also be worthwhile to investigate some highly
conserved residues of PYPAF1/NOD2 in further mutagenesis
studies, for instance, T347/T424 of PYPAF1/NOD2 as a po-
tential sensor-1 residue. Because the variants R260W (FCAS/
MWS) of PYPAF1 and R334W/Q (BS) of NOD2 correspond
to each other, it could be checked experimentally whether
R260W shows a similar dysfunctional e¡ect like R334W/Q,
indicated by an increase of basal NF-UB activity. Generally,
our structure-based multiple sequence alignment and the ob-
tained 3D models can aid in the analysis of the functional
relevance of further sequence variants, which are found with
patients and may be associated with diseases.
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